NCPE (@INFO_NCPE) profile picture

NCPE

@INFO_NCPE

‼️ We have moved to LinkedIn ‼️ You can find our LinkedIn account at https://teapaw.org/t.co/6sQdbOzmKM

 St James Hospital, Dublin
ncpe.ie
Joined June 2017
  • Tweets2K
  • Following132
  • Followers1.7K
1KMedia
Photo by NCPE (@INFO_NCPE)Photo by NCPE (@INFO_NCPE)Photo by NCPE (@INFO_NCPE)Photo by NCPE (@INFO_NCPE)Photo by NCPE (@INFO_NCPE)Photo by NCPE (@INFO_NCPE)Photo by NCPE (@INFO_NCPE)Photo by NCPE (@INFO_NCPE)Photo by NCPE (@INFO_NCPE)Photo by NCPE (@INFO_NCPE)
‼️ We are moving to LinkedIn ‼️ You can find our LinkedIn account at linkedin.com/company/ncpe-na…
Image from NCPE (@INFO_NCPE)
4
2
5
2,787
Image from NCPE (@INFO_NCPE)
2
1
414
The NCPE has completed a full HTA of Durvalumab (Imfinzi®) in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer.(1/2)
1
1
1
1
12,240
The NCPE recommends that durvalumab (Imfinzi®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*(2/2)
1
1
1,017
The NCPE have completed a Rapid Review of Ribociclib (Kisqali®) in combination with an aromatase inhibitor (AI) is indicated for the adjuvant treatment of patients with hormone receptor positive (HR+), ...(1/2)
Image from NCPE (@INFO_NCPE)
3
1
3
460
human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. A full HTA is not recommended. The NCPE recommends that ribociclib not be considered for reimbursement at the submitted price*.(2/2)
1
2
3
233
The NCPE have completed a Rapid Review of Eplontersen (Wainzua®) or the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.(1/2)
Image from NCPE (@INFO_NCPE)
1
1
2
280
A full HTA is not recommended. The NCPE recommends that eplontersen not be considered for reimbursement at the submitted price*.(2/2)
1
1
149
The NCPE have completed a Rapid Review of Spesolimab (Spevigo®) for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherap.(1/2)
Image from NCPE (@INFO_NCPE)
1
1
1
218
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of spesolimab compared with the current standard of care.(2/2)
1
1
132
The NCPE have completed a full HTA of Selumetinib (Koselugo®) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above. (1/2)
Image from NCPE (@INFO_NCPE)
1
1
2
494
The NCPE recommends that selumetinib (Koselugo®) not be considered for reimbursement*. (2/2)
1
2
205
‼️The NCPE is hiring! Would you be interested in applying for the role of Statistician at the NCPE? 📊Our Statisticians play a key role in the evaluation of drugs and other HTA related activities! ⭐️More info at: stjamescareers.ie/Job/JobDet… ‼️Closing date 15/12/2024
Image from NCPE (@INFO_NCPE)
3
3
371
The NCPE have completed a Rapid Review of Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (1/2)
Image from NCPE (@INFO_NCPE)
1
1
2
557
L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI) A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab compared with the current standard of care. (2/2)
1
1
264
The NCPE has completed a Rapid Review of Voclosporin (Lupkynis®) is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). (1/2)
Image from NCPE (@INFO_NCPE)
1
1
3
328
The NCPE recommends that voclosporin (Lupkynis®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.
1
2
158
The NCPE has completed a full HTA of Imlifidase (Idefirix®) for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. (1/2)
Image from NCPE (@INFO_NCPE)
1
1
2
319
The use of imlifidase should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients. The NCPE recommends that imlifidase be considered for reimbursement*.(2/2)
Image from NCPE (@INFO_NCPE)
1
2
169
The NCPE have completed a Rapid Review of Tenecteplase (Metalyse®) for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage in adult patients.(1/2)
Image from NCPE (@INFO_NCPE)
1
1
1
327
A full HTA is not recommended. The NCPE recommends that tenecteplase be considered for reimbursement*(2/2)
Image from NCPE (@INFO_NCPE)
1
1
141
Load more